Cardio Diagnostics Holdings, Inc. (CDIO) stock intrinsic value fair value estimate & owner earnings analysis

Cardio Diagnostics sells two blood tests for coronary heart disease built on DNA-methylation (epigenetic) markers licensed on a worldwide exclusive basis from the University of Iowa Research Foundation: Epi+Gen CHD, which estimates three-year risk of a heart attack or other coronary event, and PrecisionCHD, launched March 2023, which aims to detect existing coronary disease. Around them sit software and research offerings (Actionable Clinical Intelligence, HeartRisk, CardioInnovate360). The tests are sold to physician groups, employers, and channel partners such as YMCA locations, with an early partner-led effort in India. The business today is a scientific platform without a revenue base. Revenue was $17,065 in 2023, $34,890 in 2024, $14,825 in 2025 and $8,040 in the first half of 2026, against cash operating costs of roughly $5-6 million a year. The company holds billing codes for both tests (0439U and 0440U) and a Medicare payment rate of $854 per test set in 2025, but it does not yet have Medicare coverage, and the annual report says securing broad payer coverage "could take years." Commercial out-of-network billing through a partner was only expected to start in the second quarter of 2026. How we measured earnings. We start from operating cash flow, strip out swings in working capital, charge stock compensation as a real cost, and deduct spending on equipment and patent filings. On that basis the business consumed $4.6 million in 2022, $7.7 million in 2023, $8.7 million in 2024 and $6.8 million in 2025 (about $3.86 per share in 2025), and about $3.3 million in the first half of 2026 (roughly $6.7 million annualized). The 2025 improvement came mainly from far lower stock compensation, not from revenue. Every year since the October 2022 merger that took the company public has lost cash, so there is no positive earning power to capitalize. We treated all equipment and patent spending as a cost of staying in business, because revenue is too small for any of it to be classed as growth investment. Interest paid is trivial (about $15,000 in 2025) and the company has no bank loans or bonds, so there is no debt to subtract; what shareholders own is the cash, less whatever the business goes on to spend. Cash and runway. At June 30, 2026 the company held about $5.59 million of cash against about $0.50 million of payables and lease obligations, with 2,959,469 shares outstanding. It spent about $3.0 million in the first half of 2026, so the cash lasts roughly until mid-2027 at the current pace. Since 2024 its main funding source has been selling new shares through an at-the-market program; it sold 1,133,418 shares for $3.79 million in early 2026 alone, lifting the share count by about 62% in one quarter. Management states that cash on hand plus further share sales will fund the next 12 months. Base case ($0.00 per share). Spending continues at the first-half 2026 rate and the tests do not gain Medicare coverage or material reimbursed volume within the cash runway. That matches the record: 2025 revenue fell even after the billing codes and the $854 rate were in place. The current cash is fully consumed by about mid-2027, and anything spent after that is funded by new shares, which dilute today's holders. The value of the operating business is negative by roughly the amount of cash it will burn, so the cash and the burn cancel out. Nothing is left for today's shares. Owner earnings improved 23% in 2025 (from -$8.7 million to -$6.8 million), but year one of this case assumes no further improvement: the first-half 2026 run rate is no better than 2025, and no dated event in the filings points to a change. Bear case ($0.00 per share). The same burn, plus the listing risks named in the filings. The company did a 1-for-30 reverse split in May 2025 to fix a Nasdaq minimum-price deficiency. Because of that, a new deficiency within the following year would bring no cure period, and a proposed Nasdaq rule would suspend companies whose listed securities stay below $5 million in market value. Losing the listing would make the share sales the company depends on harder and cheaper. Shareholders are left with nothing. The company carries no debt, so this is not a case of owing more than it is worth; the cash simply runs out. Bull case ($0.66 per share). The company's own stated fallback, to delay or scale back operations if capital is not available, is used early. Spending continues through the end of 2026 (about $3.0 million), the program is then cut back, about $0.5 million settles the leases and payables, and about $2.1 million of cash is kept for shareholders. Discounted one year at 6%, that is about $0.66 per share. We did not credit Medicare coverage, commercial payer reimbursement, the India expansion or future test launches in any case. None of them is contracted or proven by the business's track record, and adoption has not yet produced meaningful revenue despite two tests on the market since 2023. If coverage were granted and test volume grew, the shares could be worth far more than any of these figures, but that outcome cannot be evidenced today. What would change the picture: a Medicare coverage decision for PrecisionCHD or Epi+Gen CHD followed by several quarters of reimbursed test volume, or a decision to stop the cash burn while meaningful cash remains. Until one of those happens, the shares are a claim on a shrinking cash balance, and each new round of share sales dilutes it further.